Cargando…
The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer
Triple negative breast (TNBC) cancer constitutes a heterogeneous group of disease with histologic and molecular differences. Complete pathologic response to neoadjuvant chemotherapy (NACT) in TNBC is associated with improved outcomes. Efforts have been made in identifying drug combinations that will...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PAGEPress Publications, Pavia, Italy
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5365000/ https://www.ncbi.nlm.nih.gov/pubmed/28382189 http://dx.doi.org/10.4081/oncol.2017.324 |
_version_ | 1782517438520229888 |
---|---|
author | Castrellon, Aurelio Bartolome Pidhorecky, Ihor Valero, Vicente Raez, Luis Estuardo |
author_facet | Castrellon, Aurelio Bartolome Pidhorecky, Ihor Valero, Vicente Raez, Luis Estuardo |
author_sort | Castrellon, Aurelio Bartolome |
collection | PubMed |
description | Triple negative breast (TNBC) cancer constitutes a heterogeneous group of disease with histologic and molecular differences. Complete pathologic response to neoadjuvant chemotherapy (NACT) in TNBC is associated with improved outcomes. Efforts have been made in identifying drug combinations that will increase the response rate to preoperative chemotherapy. In this review we present recent studies that have incorporated carboplatin (Cb) in the NACT of TNBC. We discuss the homologous recombination deficiency score and the somatic or germline mutation for BRCA as potential biomarkers for future selection of patients that could benefit from the addition of Cb to NACT. |
format | Online Article Text |
id | pubmed-5365000 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | PAGEPress Publications, Pavia, Italy |
record_format | MEDLINE/PubMed |
spelling | pubmed-53650002017-04-05 The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer Castrellon, Aurelio Bartolome Pidhorecky, Ihor Valero, Vicente Raez, Luis Estuardo Oncol Rev Review Triple negative breast (TNBC) cancer constitutes a heterogeneous group of disease with histologic and molecular differences. Complete pathologic response to neoadjuvant chemotherapy (NACT) in TNBC is associated with improved outcomes. Efforts have been made in identifying drug combinations that will increase the response rate to preoperative chemotherapy. In this review we present recent studies that have incorporated carboplatin (Cb) in the NACT of TNBC. We discuss the homologous recombination deficiency score and the somatic or germline mutation for BRCA as potential biomarkers for future selection of patients that could benefit from the addition of Cb to NACT. PAGEPress Publications, Pavia, Italy 2017-03-17 /pmc/articles/PMC5365000/ /pubmed/28382189 http://dx.doi.org/10.4081/oncol.2017.324 Text en ©Copyright A.B. Castrellon et al. 2017 http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Castrellon, Aurelio Bartolome Pidhorecky, Ihor Valero, Vicente Raez, Luis Estuardo The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer |
title | The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer |
title_full | The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer |
title_fullStr | The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer |
title_full_unstemmed | The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer |
title_short | The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer |
title_sort | role of carboplatin in the neoadjuvant chemotherapy treatment of triple negative breast cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5365000/ https://www.ncbi.nlm.nih.gov/pubmed/28382189 http://dx.doi.org/10.4081/oncol.2017.324 |
work_keys_str_mv | AT castrellonaureliobartolome theroleofcarboplatinintheneoadjuvantchemotherapytreatmentoftriplenegativebreastcancer AT pidhoreckyihor theroleofcarboplatinintheneoadjuvantchemotherapytreatmentoftriplenegativebreastcancer AT valerovicente theroleofcarboplatinintheneoadjuvantchemotherapytreatmentoftriplenegativebreastcancer AT raezluisestuardo theroleofcarboplatinintheneoadjuvantchemotherapytreatmentoftriplenegativebreastcancer AT castrellonaureliobartolome roleofcarboplatinintheneoadjuvantchemotherapytreatmentoftriplenegativebreastcancer AT pidhoreckyihor roleofcarboplatinintheneoadjuvantchemotherapytreatmentoftriplenegativebreastcancer AT valerovicente roleofcarboplatinintheneoadjuvantchemotherapytreatmentoftriplenegativebreastcancer AT raezluisestuardo roleofcarboplatinintheneoadjuvantchemotherapytreatmentoftriplenegativebreastcancer |